140 related articles for article (PubMed ID: 6407810)
1. Hexamethylmelamine and pentamethylmelamine: an update.
Hahn DA
Drug Intell Clin Pharm; 1983 Jun; 17(6):418-24. PubMed ID: 6407810
[TBL] [Abstract][Full Text] [Related]
2. Pentamethylmelamine: review of an aqueous analog of hexamethylmelamine.
Foster BJ; Clagett-Carr K; Hoth D; Leyland-Jones B
Cancer Treat Rep; 1986 Mar; 70(3):383-9. PubMed ID: 3082512
[TBL] [Abstract][Full Text] [Related]
3. Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
Broggini M; Rossi C; Colombo T; D'Incalci M
Cancer Treat Rep; 1982 Jan; 66(1):127-33. PubMed ID: 6796267
[TBL] [Abstract][Full Text] [Related]
4. Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.
Muindi JR; Newell DR; Smith IE; Harrap KR
Br J Cancer; 1983 Jan; 47(1):27-33. PubMed ID: 6401427
[TBL] [Abstract][Full Text] [Related]
5. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
Stehman FB; Ehrlich CE; Callangan MF
Gynecol Oncol; 1984 Feb; 17(2):189-95. PubMed ID: 6423460
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of pentamethylmelamine.
Ajani JA; Cabanillas FF; Bodey GP
Cancer Treat Rep; 1982 May; 66(5):1227-8. PubMed ID: 6805950
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
[TBL] [Abstract][Full Text] [Related]
8. Hexamethylmelamine as a single second-line agent in ovarian cancer.
Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
Gynecol Oncol; 1990 Jan; 36(1):93-6. PubMed ID: 2104819
[TBL] [Abstract][Full Text] [Related]
9. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Foster BJ; Clagett-Carr K; Marsoni S; Simon R; Leyland-Jones B
Cancer Treat Rep; 1986 Aug; 70(8):1003-14. PubMed ID: 3089597
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Kardinal CG; Luce JK
Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice.
Broggini M; Colombo T; D'Incalci M; Donnelli MG; Gescher A; Garattini S
Cancer Treat Rep; 1981; 65(7-8):669-72. PubMed ID: 6788370
[TBL] [Abstract][Full Text] [Related]
12. Hexamethylmelamine chemotherapy for disseminated endometrial cancer.
Seski JC; Edwards CL; Copeland LJ; Gershenson DM
Obstet Gynecol; 1981 Sep; 58(3):361-3. PubMed ID: 6791063
[TBL] [Abstract][Full Text] [Related]
13. Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine).
Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
Cancer Treat Rev; 1991 Mar; 18 Suppl A():23-9. PubMed ID: 1904305
[TBL] [Abstract][Full Text] [Related]
14. Hexamethylmelamine. An evaluation of its role in the therapy of cancer.
Legha SS; Slavik M; Carter SK
Cancer; 1976 Jul; 38(1):27-35. PubMed ID: 820422
[TBL] [Abstract][Full Text] [Related]
15. Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer.
Wharton JT; Rutledge F; Smith JP; Herson J; Hodge MP
Am J Obstet Gynecol; 1979 Apr; 133(7):833-44. PubMed ID: 219695
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of pentamethylmelamine: a clinical and pharmacologic study.
Ihde DC; Dutcher JS; Young RC; Cordes RS; Barlock AL; Hubbard SM; Jones RB; Boyd MR
Cancer Treat Rep; 1981; 65(9-10):755-62. PubMed ID: 6791819
[TBL] [Abstract][Full Text] [Related]
17. Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.
Lee CR; Faulds D
Drugs; 1995 Jun; 49(6):932-53. PubMed ID: 7641606
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion.
Casper ES; Gralla RJ; Lynch GR; Jones BR; Woodcock TM; Gordon C; Kelsen DP; Young CW
Cancer Res; 1981 Apr; 41(4):1402-6. PubMed ID: 6783296
[TBL] [Abstract][Full Text] [Related]
19. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
Boven E; Nauta MM; Schlüper HM; Erkelens CA; Pinedo HM
Cancer Chemother Pharmacol; 1986; 18(2):124-8. PubMed ID: 3098444
[TBL] [Abstract][Full Text] [Related]
20. cis-Dichlorodiammineplatinum (II) and hexamethylmelamine in advanced ovarian carcinoma: a phase II study.
Lund B; Aabo K; Rørth M; Hansen HH
Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1089-92. PubMed ID: 6819145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]